In the past decades, the striking development of cationic polypeptides and cell-penetrating
peptides (CPPs) tailored for small interfering RNA (siRNA) delivery has been fuelled by the …

Numerous endosomolytic agents have been developed to facilitate nanoparticle escape
from the endosome and prevent destruction in the lysosome. Many endosomolytic agents …

The development of carriers for the delivery of oligonucleotide therapeutics is essential for
the successful translation of gene therapies to the clinic. In the present study, a delivery …

Degenerative diseases are marked by continuous and progressive deterioration of the
function of cells which is not caused by any underlying trauma or infection. The economic …

Background: The development of modern nanomedicine greatly depends on the
involvement of novel materials as drug delivery system. In order to maximize the therapeutic …

Gene therapy is the most effective treatment option for diseases, but its effectiveness is
affected by the choice and design of gene carriers. The genes themselves have to pass …

The development of non-viral gene delivery systems, with the capacity to overcome most of
the biological barriers facing gene delivery, is challenging. We have developed peptide …

Aim: To develop a peptide/phospholipid hybrid system for gastrin-releasing peptide receptor
(GRPR)-targeted delivery of pDNA or siRNA. Materials & methods: A multifunctional GRPR …

Background: Genetic drugs have aroused much attention in the past twenty years. RNA
interference (RNAi) offers novel insights into discovering potential gene functions and …

This Chapter summarizes the methods for CPP-conjugated oligonucleotide-based agents
with the potential to use as the therapeutic drugs. The methods for gene silencing (or …